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Abstract Hereditary multiple exostoses (HME) also known
as multiple osteochondromas represent one of the most fre-
quent bone tumor disorder in humans. Its clinical presentation
is characterized by the presence of multiple benign cartilage-
capped tumors located most commonly in the juxta-
epiphyseal portions of long bones. HME are usually inherited
in autosomal dominant manner, however de novo mutations
can also occur. In most patients, the disease is caused by
alterations in the EXT1 and EXT2 genes. In this study we
investigated 33 unrelated Polish probands with the clinical
and radiological diagnosis of HME by means of Sanger se-
quencing and MLPA for all coding exons of EXT1 and EXT2.
We demonstrated EXT1 and EXT2 heterozygous mutations in
18 (54.6 %) and ten (30.3 %) probands respectively, which
represents a total of 28 (84.9 %) index cases. Sequencing
allowed for the detection of causative changes in 26
(78.8 %) probands, whereas MLPA showed intragenic dele-
tions in two (6.1 %) further cases (15 mutations represented
novel changes). Our paper is the first report on the results of
exhaustive mutational screening of both EXT1/EXT2 genes in
Polish patients. The proportion of EXT1/EXT2 mutations in
our group was similar to other Caucasian cohorts. However,
we found that EXT1 lesions in Polish patients cluster in exons
1 and 2 (55.6 % of all EXT1 mutations). This important
finding should lead to the optimization of cost-effectiveness
rate of HME diagnostic testing. Therefore, the diagnostic
algorithm for HME should include EXT1 sequencing (starting
with exons 1–2), followed by EXT2 sequencing, and
MLPA/qPCR for intragenic copy number changes.
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Introduction
Hereditary multiple exostoses (HME) also referred to as mul-
tiple osteochondromas (MO) are one of the most common
benign bone tumors with an estimated prevalence rate of 1 per
50,000 in European population (Hennekam 1991; Schmale
et al. 1994). The disorder is usually inherited in autosomal
dominant manner, however de novomutations are also known
to occur. HME are highly penetrant (close to 100%) and show
significant variability in symptoms expression and the age of
onset, which varies from 2 to 15 years (Schmale et al. 1994).
Clinical picture of HME involves formation of benign
cartilage-capped tumors most frequently located in the juxta-
epiphyseal parts of long bones, especially around the knee
(femur, tibia), the wrist, the proximal humerus, the proximal
fibula, and the ribs. Exostoses can also occur in scapula and
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pelvis, but neither mandible nor the calvarium are involved
(Shapiro et al. 1979; Schmale et al. 1994). Lesions are usually
inconspicuous at birth and tend to grow in number and size
through childhood and adolescence until the closure of growth
plates in puberty. It has been suggested that the formation of
exostoses in HME patients is the consequence of a two-hit
model in which predisposition for tumor development due to
germline mutation and a second somatic “hit” are necessary
for the development of exostoses (Mertens et al. 1994). Due to
the disruption of growth plates osteochondromas may lead to
the various skeletal deformities, such as limb shortening,
angular deviation of long bones (especially the ulna),
Madelung deformity, movement restrictions, as well as short
stature. In addition, exostoses can cause nerve or blood vessel
compression, joint limitations, and in some cases (up to 5 %)
can transform into malignant tumors such as chondrosarcoma
or osteosarcoma (Hennekam 1991; Wicklund et al. 1995).
HME result from the mutations of at least two putative
tumor suppressor genes, i.e., EXT1 located on chromosome
8q24.1 and EXT2—located on chromosome 11p11 (Ahn et al.
1995; Stickens et al. 1996; Wuyts et al. 1996). Third region
with a hypothetical EXT3 gene was mapped to the chromo-
some 19p in linkage studies of EXT1/EXT2 negative family,
nevertheless causative mutations associated with this locus
have not been identified to date (Le Merrer et al. 1994).
Mutations in EXT1 gene underlie 56–78 % of HME cases,
whereas in EXT2—21–44 % (Jennes et al. 2009). Both EXT1
and EXT2 genes encode for glycotransferase enzymes of
endoplasmic reticulum (N-Acetylglucosamine transferase
and D-glucuronic acid transferase respectively) involved in
the synthesis of heparan sulfate and proteoglycans (Busse
et al. 2007). Mutations in these genes have different patterns
of concentration.While lesions ofEXT1 are scattered through-
out the gene, mutations in EXT2 tend to cluster in the first N-
terminal part of the protein (Busse et al. 2007; Jennes et al.
2009).
In this study we investigated 33 unrelated Polish index
cases with the clinical and radiological diagnosis of HME.
We extend the mutational spectrum of the genes and report our
diagnostic experience regarding EXT1 and EXT2 screening in
Polish patients, who were not represented so far in published
molecular studies.
Table 1 Sequences of the
primers used for EXT1 and
EXT2 gene amplification
and sequencing
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Materials and methods
Patients and clinical information
Thirty three unrelated index cases of Polish ethnicity who
were clinically and radiographically suspected of HME were
recruited for this study. The inclusion criteria involved two or
more exostoses diagnosed upon clinical assessment and/or X-
ray imaging. Twenty five probands had a positive family
history, while eight were sporadic. Blood was collected from
all index cases as well as from affected and unaffected avail-
able family members. The local ethics committee approved
the study and written informed consent was obtained from all
subjects or their legal guardians.
Molecular screening
Genomic DNA was isolated from whole blood according to
the conventional salting-out method. The coding sequences of
both EXT1 and EXT2 genes (GenBank accession number
NM_000127 and NM_207122.1), comprised of all coding
exons, and the flanking intronic regions were amplified in a
set of PCR reactions and directly sequenced by means of dye-
terminator chemistry (kit v.3, ABI 3130XL). Sequences of the
primers used for amplification and sequencing PCR reactions
are given in Table 1 (primers for EXT1 were as described
elsewhere by Baasanjav et al. 2010). Multiplex ligation-
dependent probe amplification (MLPA) for all exons of the
EXT1 and EXT2 was performed with the use of commercial
Table 2 List of mutations in EXT1 and EXT2 genes identified in our MO probands
Gene Exon/introna Nucleotide change Protein change Type of mutation Case Reference
EXT1 1 c.15dupA p.R6Tfsa24 frameshift F Jennes et al. (2009)
1 c.214G>T p.E72a nonsense F Wuyts et al. (2005)
1 c.218delA p.N73Tfsa63 frameshift S Jennes et al. (2009)
1 c.365delA p.Q122Qfsa14 frameshift F Novel mutation
1 c.482delT p.L161a frameshift F Novel mutation
1 c.698delC p.S233Lfsa19 frameshift F Novel mutation
1 c.812A>G p.Y271C missense F Fokkema et al. (2011)
2 c.1019G>A p.R340H missense F Raskind et al. (1998); Cheung et al. (2001)
2 c.1036A>G p.R346G missense F Signori et al. (2007)
IVS2 c.1056+1G>C skipping exon 2 splicing F Novel mutation
6 c.1431delCb p.P477Lfsa11 frameshift Fb Jennes et al. (2008)
6 c.1454delA p.H485Lfsa3 frameshift F Novel mutation
6 c.1469delT p.L490Rfsa9 frameshift F Ahn et al. (1995); Sarrión et al. (2013)
9/IVS9 c.1859_1883+1dup p.K628Kfsa1 frameshift S Novel mutation
IVS9 c.1883+1G>T skipping exon 9 splicing F Novel mutation
10 c.1902_1903insTA p.S635Yfsa9 frameshift S Novel mutation
10 c.2006delC p.P669Qfsa4 frameshift F Novel mutation
EXT2 2 c.273delT p.F91Lfsa21 frameshift F Novel mutation
2 c.310delA p.I104Sfsa8 frameshift F Novel mutation
5 c.722C>T p.Q258a nonsense S Francannet et al. (2001)
5 c.817C>T p.Q273a nonsense F Vanita et al. (2009)
5/IVS5 c.934_939+3del p.L312_Q313del frameshift/splicing F Novel mutation
7 c.1110delGc p.M370Ifsa66 frameshift S/Fc Novel mutation
8 c.1177delC p.R393Gfsa43 frameshift F Novel mutation
7–10 exons 7–10 deletion deletion S Novel mutation
8 exon 8 deletion deletion F Jennes et al. (2009)
a The reference sequences for EXT1 and EXT2 genes are NM_000127 and NM_207122.1, respectively
Only deleted exons in EXT2 are numbered according to the reference sequence NM_000401.3, as counted by the manufacturer of “SALSA MLPA
probemix P215-B2 EXT” description version 10 (MRC Holland)
F familial
S sporadic
bmutation detected in two unrelated patients, both familial cases
cmutation detected in two unrelated patients, one sporadic and one familial case
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kit P215-B1 per the manufacturer’s protocol (MRC Holland).
Data was intra-normalized by dividing the area of each peak
by the overall area of the reference probes’ peaks in the
probemix. Inter-sample normalization was obtained by com-
paring the investigated samples to several reference control
samples (healthy individuals) run in the same experiment.
Relative peak areas ranging from 0.67 to 1.33 were considered
normal, below 0.67—deleted, and above 1.33—duplicated
(Schouten et al. 2002). DNA of all index cases was screened
for both point mutations and intragenic copy number changes
involving EXT1 and EXT2 gene, by means of sequencing and
MLPA. Next, co-segregation testing was performed in all
affected and unaffected family members to check for co-
occurrence of the detected mutation with the phenotype.
Alternatively, parental studies were done in sporadic cases to
confirm a de novo occurrence of the alterations. Detected
mutations were referred to Human Gene Mutation Database
(HGMD) Professional 2013.4 (HGMD) and Leiden Open
Variation Database (LOVD) version 2.0 (Fokkema et al.
2011). Pathogenicity of all identified missense variants was
additionally assessed in silico using Mutation Taster 2,
Polyphen2, and SIFT software.
Results
We found EXT1 and EXT2 heterozygous mutations in 28 out
33 (84.9 %) unrelated probands from our cohort. In total, we
demonstrated 26 different mutational hits, since two of them
were recurrent. Eighteen causative alterations (54.6 %) were
identified in EXT1, while ten (30.3 %) were shown in EXT2.
The remaining five cases (15.1 %) were negative for both
EXT1 and EXT2 mutations. DNA sequencing has allowed for
the detection of causative changes in 26 (78.8 %) probands,
whereas MLPA showed intragenic copy number changes in
two (6.1 %) further cases. Out of 28 molecularly confirmed
unrelated probands, six cases (21.4 %) occurred due to de
novomutation while 22 (78.6 %) inherited the disease causing
variant from an affected parent. According to HGMD®
Professional 2013.4 and LOVD v.2.0 databases, out of 26
different mutations demonstrated in this study, 15 alterations
were novel, whereas 11 were previously reported elsewhere
(HGMD, Fokkema et al. 2011). Nine out of the 15 novel
single nucleotide variants (SNVs) were identified in EXT1
and six in EXT2. For the description of the mutations and
their reference to literature data, see Table 2. Out of 28
mutations detected by us, 23 (82.1 %) represented inactivating
variants (17 frameshift, three nonsense, three splicing muta-
tions). The remaining causative changes were two intragenic
deletions (both in EXT2) and three missense substitutions (all
in EXT1).
In all sporadic cases, presence of the mutation was exclud-
ed in both healthy parents, thus confirming their de novo
occurrence in the probands. In familial cases, the identified
alterations were checked for co-segregation with the pheno-
type and were not shown in the unaffected family members.
Furthermore, all three missense variants were predicted to be
probably damaging in most of the in silico analyses performed
by us with the use of Mutation Taster 2, PolyPhen2, and SIFT
software (Table 3).
Discussion
Hereditary multiple exostoses is a relatively frequent autoso-
mal dominant bone disorder resulting from heterozygous
inactivating mutations of EXT1 and EXT2 genes. Both gene
products represent tumor suppressor proteins involved in
Table 3 Location of the missense mutations identified in our patients in reference to the EXT1 domain organization. Pathogenicity of each variant was





EXT1 mutation at cDNA
and protein level




SIFT score PolyPhen-2 score
1 AD
(familial)








Known c.1036A>G (p.R346G) exostosin domain disease causing 0.02 (damaging) 0.940
(possibly damaging)
AD autosomal dominant
MutationTaster 2: MutationTaster employs a Bayes classifier to eventually predict the disease potential of an alteration. The Bayes classifier is fed with
the outcome of all tests and the features of the alterations and calculates probabilities for the alteration to be either a disease mutation or a harmless
polymorphism
SIFT (sorting intolerant from tolerant): the amino acid substitution is predicted damaging if the score is <0.05, and tolerated if the score is ≥0.05
PolyPhen-2: score ranges from 0 to 1. The amino acid substitution is predicted damaging if the score is above 0.85
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heparan sulphate (HS) synthesis and cartilage formation.
EXT1 and EXT2 act in a hetero-oligomeric complex and
catalyze the elongation of HS chains (McCormick et al.
2000; Busse et al. 2007). Mutations in EXT1 or EXT2 are
believed to result in reduced level of HS biosynthesis as well
as in shortening of HS chains, what disrupts the gradient of
morphogens and impair signal transduction in the epiphyseal
growth plate in the cartilage. This leads to the loss of cell
polarity and once occur in the peripheral part of bone, the cells
maintain to proliferate, bring other wild-type cells along and
grow into a cartilaginous cap, i.e., osteochondroma (Jones
2011; de Andrea and Hogendoorn 2012).
There are only a few reports on large HME cohorts studied
with a comprehensive molecular diagnostic testing including
both gene sequencing and quantitative assays, such as MLPA
or quantitative PCR (qPCR) for all exons (Porter et al. 2004;
Jennes et al. 2009; Ciavarella et al. 2013). Importantly, such
studies have never been performed in Polish patients. Thus,
our analysis represents the first source of information on
molecular cause, frequencies, and the proportion of EXT1
and EXT2 mutations in Polish patients affected by HME. In
our study, we demonstrated EXT1 and EXT2 mutations in 28
(84.9 %) out of 33 unrelated probands, which represents a
similar diagnostic success rate to previously published reports
in which this value varied from 70 to 95% (Jennes et al. 2009;
Ciavarella et al. 2013). Importantly, in EXT1/EXT2 positive
Polish patients, EXT1 mutations were found almost twice
more frequently than EXT2 mutations (18 vs 10 hits, i.e.,
64.3 % vs 35.7 % respectively), which is also in accordance
with the literature data (Jennes et al. 2009). The majority of
MO causing changes (75–80 %) represent inactivating muta-
tions, i.e., nonsense, frameshift, and splice-site (Jennes et al.
2009). Likewise, as shown in Table 2, 23 out of 28 mutations
(82 %) detected in our cohort were also leading to the prema-
ture truncation of the protein product. In addition, we found
three different EXT1 missense substitutions associated with
HME phenotype: p.Y271C, p.R340H, and p.R346G
(Fokkema et al. 2011; Raskind et al. 1998; Signori et al.
2007). All missense substitutions were located within
exostosin domain of EXT1 and were predicted to be probably
damaging to the protein function in computational analyses by
means of PolyPhen2, SIFT, and Mutation Taster2 software.
An overview of missense mutations, along with their intra-
genic location, and predictive values of in silico analyses is
presented in Table 3.
In keeping with the past reports, EXT1 mutations are usu-
ally distributed throughout the entire protein sequence, while
EXT2 lesions cluster in the first half of the protein (Jennes
et al. 2009). However, in a large Italian cohort described by
Ciavarella et al. (2013), 50.1 % of all EXT1 mutations were
localized in exons 1 and 2. Our findings based on Polish
patients support the hypothesis that there may be an excess
of mutations in the first two exons of EXT1. In our cohort,
mutation in exons 1 or 2 was identified in ten of 18 (55.6 %)
EXT1mutation carriers, which comprised 30.3% of our initial
cohort (ten probands out of 33). Therefore, we propose that
diagnostic screening of HME Polish patients should start with
the sequencing of the first two exons of EXT1, followed by
sequencing of the rest of the gene. Next, in the case of negative
results, we suggest EXT2 sequencing followed by copy num-
ber assays for EXT1/EXT2 exons.
To conclude, our paper is the first report that provides the
results of exhaustive mutational screening of both HME relat-
ed genes (EXT1/EXT2) in a Polish cohort. The ratio of EXT1
vs EXT2 gene lesions in our study is in full accordance with
the relative mutational frequencies published previously for
other Caucasian cohorts. We also expand here the mutational
spectrum associated with MOs by describing the 15 novel
pathogenic alterations in the EXT1 and EXT2 genes. In addi-
tion, although based on a small sample, our study supports the
hypothesis that at least in certain groups of patients EXT1
mutations may cluster within the first two exons of the gene.
This important finding should influence the diagnostic algo-
rithm, thereby leading to the optimization of cost-
effectiveness rate in HME genetic testing. Furthermore, we
showed that intragenic EXT1/2 deletions may account for a
non-negligible proportion of HME causative mutations.
Therefore, we propose that MLPA or qPCR should be imple-
mented into routine molecular diagnostic of the EXT1/2 genes,
especially if the sequence analysis detects no pathogenic
alteration.
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